Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.

Japanese circulation journal - 1 Feb 1998

Nagao K, Satou K, Watanabe I, Arima K, Yamashita M, Ooiwa K, Kanmatsuse K

Abstract excerpt

The effects and problems of intravenous thrombolytic therapy with a bolus injection of mutant tissue plasminogen activator (t-PA) were investigated in 34 patients with first acute myocardial infarction (AMI). In contrast, 114 patients were selected from 1,003 patients with AMI for treatment using intravenous infusion urokinase (UK). Angiography of these 148 patients revealed a complete occlusion of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Aged
Share to Coronary Angiography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myocardial Infarction

Share to Recombinant Proteins

Share to Tissue Plasminogen Activator

Share to Treatment Outcome

Source

Identifiers

PMID: 9559429
DOI: 10.1253/jcj.62.111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.PMID 9559429Read ↗

Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.Semantic proximity Read ↗

Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.Semantic proximity Read ↗

Newer thrombolytic agents.Semantic proximity Read ↗

[Mutant t-PA compared with native t-PA in acute myocardial infarction].Semantic proximity Read ↗

Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.Semantic proximity Read ↗

Labeling of human clots in vitro with an active-site mutant of t-PA.Semantic proximity Read ↗

Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.Semantic proximity Read ↗

The Differences in Thrombolytic Effects of Administrated Recombinant t-PA between Japanese and CaucasiansSemantic proximity Read ↗

Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.Semantic proximity Read ↗

Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.Semantic proximity Read ↗

Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.Semantic proximity Read ↗

Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.